Logo image of STSA

Satsuma Pharmaceuticals Inc (STSA) Stock Fundamental Analysis

USA - NASDAQ:STSA - US80405P1075 - Common Stock

1.1 USD
-0.01 (-0.9%)
Last: 6/7/2023, 8:00:00 PM
1.07 USD
-0.03 (-2.73%)
After Hours: 6/7/2023, 8:00:00 PM
Fundamental Rating

2

Taking everything into account, STSA scores 2 out of 10 in our fundamental rating. STSA was compared to 192 industry peers in the Pharmaceuticals industry. While STSA seems to be doing ok healthwise, there are quite some concerns on its profitability. STSA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

STSA had negative earnings in the past year.
In the past year STSA has reported a negative cash flow from operations.
In the past 5 years STSA always reported negative net income.
In the past 5 years STSA always reported negative operating cash flow.
STSA Yearly Net Income VS EBIT VS OCF VS FCFSTSA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 -20M -40M -60M

1.2 Ratios

The profitability ratios for STSA are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
STSA Yearly ROA, ROE, ROICSTSA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 0 -2K -4K

1.3 Margins

STSA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
STSA Yearly Profit, Operating, Gross MarginsSTSA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022

More info and screens

6

2. Health

2.1 Basic Checks

STSA has more shares outstanding than it did 1 year ago.
STSA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
STSA Yearly Shares OutstandingSTSA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 10M 20M 30M
STSA Yearly Total Debt VS Total AssetsSTSA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -6.49, we must say that STSA is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -6.49, STSA is not doing good in the industry: 67.28% of the companies in the same industry are doing better.
There is no outstanding debt for STSA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.49
ROIC/WACCN/A
WACCN/A
STSA Yearly LT Debt VS Equity VS FCFSTSA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 7.44 indicates that STSA has no problem at all paying its short term obligations.
STSA has a better Current ratio (7.44) than 71.89% of its industry peers.
A Quick Ratio of 7.44 indicates that STSA has no problem at all paying its short term obligations.
STSA has a better Quick ratio (7.44) than 73.27% of its industry peers.
Industry RankSector Rank
Current Ratio 7.44
Quick Ratio 7.44
STSA Yearly Current Assets VS Current LiabilitesSTSA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

STSA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -12.92%.
EPS 1Y (TTM)-12.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.73%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 15.03% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y56.57%
EPS Next 2Y31.44%
EPS Next 3Y22.81%
EPS Next 5Y15.03%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
STSA Yearly Revenue VS EstimatesSTSA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 10M 20M 30M
STSA Yearly EPS VS EstimatesSTSA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2 -3 -4 -5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

STSA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for STSA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
STSA Price Earnings VS Forward Price EarningsSTSA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
STSA Per share dataSTSA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

STSA's earnings are expected to grow with 22.81% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.44%
EPS Next 3Y22.81%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for STSA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Satsuma Pharmaceuticals Inc

NASDAQ:STSA (6/7/2023, 8:00:00 PM)

After market: 1.07 -0.03 (-2.73%)

1.1

-0.01 (-0.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-11 2023-05-11/amc
Earnings (Next)08-07 2023-08-07/amc
Inst Owners0.05%
Inst Owner Change0%
Ins Owners11.58%
Ins Owner Change0%
Market Cap36.47M
Revenue(TTM)N/A
Net Income(TTM)-64832000
Analysts76.36
Price Target2.04 (85.45%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-46.2%
Min EPS beat(2)-89.37%
Max EPS beat(2)-3.02%
EPS beat(4)1
Avg EPS beat(4)-20.77%
Min EPS beat(4)-89.37%
Max EPS beat(4)13.37%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-11.11%
EPS NQ rev (1m)-10.1%
EPS NQ rev (3m)-6.45%
EPS NY rev (1m)0%
EPS NY rev (3m)-39.18%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.97
P/tB 0.97
EV/EBITDA N/A
EPS(TTM)-2.01
EYN/A
EPS(NY)-0.6
Fwd EYN/A
FCF(TTM)-1.48
FCFYN/A
OCF(TTM)-1.47
OCFYN/A
SpS0
BVpS1.14
TBVpS1.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 107.18%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.44
Quick Ratio 7.44
Altman-Z -6.49
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)921.09%
Cap/Depr(5y)764.56%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.73%
EPS Next Y56.57%
EPS Next 2Y31.44%
EPS Next 3Y22.81%
EPS Next 5Y15.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y3.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year36.2%
EBIT Next 3Y24.32%
EBIT Next 5Y15.58%
FCF growth 1Y-11.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-28.53%
OCF growth 3YN/A
OCF growth 5YN/A

Satsuma Pharmaceuticals Inc / STSA FAQ

What is the fundamental rating for STSA stock?

ChartMill assigns a fundamental rating of 2 / 10 to STSA.


What is the valuation status of Satsuma Pharmaceuticals Inc (STSA) stock?

ChartMill assigns a valuation rating of 2 / 10 to Satsuma Pharmaceuticals Inc (STSA). This can be considered as Overvalued.


What is the profitability of STSA stock?

Satsuma Pharmaceuticals Inc (STSA) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for STSA stock?

The Earnings per Share (EPS) of Satsuma Pharmaceuticals Inc (STSA) is expected to grow by 56.57% in the next year.